Moors & Cabot Inc. Sells 19 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moors & Cabot Inc. decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 797 shares of the biopharmaceutical company’s stock after selling 19 shares during the period. Moors & Cabot Inc.’s holdings in Regeneron Pharmaceuticals were worth $838,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quent Capital LLC raised its position in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares during the last quarter. CreativeOne Wealth LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $200,000. Gamco Investors INC. ET AL bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $230,000. Gabelli Funds LLC boosted its holdings in Regeneron Pharmaceuticals by 3.0% during the first quarter. Gabelli Funds LLC now owns 1,859 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 54 shares during the last quarter. Finally, 1832 Asset Management L.P. boosted its holdings in Regeneron Pharmaceuticals by 24.5% during the first quarter. 1832 Asset Management L.P. now owns 2,806 shares of the biopharmaceutical company’s stock worth $2,701,000 after purchasing an additional 552 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $738.00 on Friday. The stock has a 50 day simple moving average of $945.07 and a 200 day simple moving average of $1,026.63. The stock has a market cap of $81.10 billion, a P/E ratio of 18.26, a PEG ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on REGN shares. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Morgan Stanley dropped their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.